ArticleJAMA oncology2020

Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.

Kelly M Kenzik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.